首页 500强 活动 榜单 商业 科技 领导力 专题 品牌中心
杂志订阅

获得“超级免疫”,意味着什么?

SOPHIE MELLOR
2022-01-04

已接种疫苗者若出现突破性感染,可形成“超级免疫”。

文本设置
小号
默认
大号
Plus(0条)

如果你近期曾经感染新冠并已恢复,现在是否可以随心所欲想干什么就干什么?最新的研究表明,曾经感染新冠确实能大大降低你再次感染的几率。

虽然一些早期研究认为,如果曾经感染奥密克戎,极可能会产生相应抗体,但要知道,大多数人并不能确定感染的是哪一种新冠毒株。据美国疾病控制与预防中心估计,在美国,奥密克戎变种占目前全部新冠感染病例的59%,德尔塔变种占剩余的41%。眼下,关于每种毒株的再感染率几乎没有任何数据。不过,南非一篇预印本研究论文发现,奥密克戎感染或许会增加对德尔塔变种的免疫力。

这项研究由非洲健康研究所(Africa Health Research Institute)开展,正是该所研究人员首次发现,两剂辉瑞疫苗对奥密克戎的免疫应答较弱。他们在本次研究中追踪了13个人,其中11人感染了奥密克戎毒株。他们发现,在参与者加入研究两周后,曾感染奥密克戎的人对德尔塔的抗体反应增加了四倍。同时,他们发现,奥密克戎感染对再次感染同种毒株的保护力提高了14倍。

这些发现意味着,奥密克戎可以取代德尔塔成为新冠病毒的主要毒株。由哈迪贾·可汗领导的科学家团队在研究结果中写道:“研究结果与奥密克戎将取代德尔塔变种的结论一致,因为奥密克戎变种可以引发免疫,中和德尔塔病毒,从而降低再次感染德尔塔病毒的可能性。”

科学家们指出,如果奥密克戎取代了德尔塔,且如果奥密克戎确实如早期研究结果所述不易产生重症,“新冠肺炎重症的发病率将降低,病毒感染对个体和社会的影响将变小。”尽管存在上述预测,世界卫生组织仍警告称,现在断言奥米克戎总体上是否更温和还为时过早。

俄勒冈健康与科学大学(Oregon Health & Science University)的另外一项研究发现,已接种疫苗者若出现突破性感染,可形成“超级免疫”。该研究对比了该大学52名曾接种过辉瑞疫苗但出现突破性感染的员工的血液样本,这些员工感染的毒株包括阿尔法、贝塔、伽马和德尔塔。

研究发现,突破性感染出现后产生的抗体,比接种完辉瑞疫苗第二针两周后产生的抗体更多、更有效。“没有比这更好的免疫应答了,”报告作者、俄勒冈健康与科学大学医学院助理教授菲卡杜·塔费瑟说。

“我们没有专门研究奥密克戎毒株的情况,”塔费瑟补充说,“但根据研究结果,我们预计,奥密克戎毒株产生的突破性感染将在已接种疫苗的人群中产生同样强烈的免疫反应。”

鉴于这波疫情中感染新冠肺炎病毒的人数众多,如感染者的免疫力提高,或许意味着疫情可能很快会缓解。“急速上升的感染人数正在逐步建立起群体免疫力。这将对抑制未来的疫情扩散至关重要,”凯撒家庭基金会(Kaiser Family Foundation)全球卫生政策副主任约书亚·米肖向Vox表示。

然而,奥密克戎已被证明能够很好地避开以前不同变种的感染。来自南非的预印本研究论文发现,南非第四波疫情期间,再次感染奥密克戎的风险远远高于该国第二波和第三波疫情期间再次感染的风险,上两波疫情分别以贝塔和德尔塔为主。伦敦帝国理工学院的另一项研究发现,再次感染奥密克戎变种的风险是德尔塔变种的5.4倍。(财富中文网)

译者:Agatha

如果你近期曾经感染新冠并已恢复,现在是否可以随心所欲想干什么就干什么?最新的研究表明,曾经感染新冠确实能大大降低你再次感染的几率。

虽然一些早期研究认为,如果曾经感染奥密克戎,极可能会产生相应抗体,但要知道,大多数人并不能确定感染的是哪一种新冠毒株。据美国疾病控制与预防中心估计,在美国,奥密克戎变种占目前全部新冠感染病例的59%,德尔塔变种占剩余的41%。眼下,关于每种毒株的再感染率几乎没有任何数据。不过,南非一篇预印本研究论文发现,奥密克戎感染或许会增加对德尔塔变种的免疫力。

这项研究由非洲健康研究所(Africa Health Research Institute)开展,正是该所研究人员首次发现,两剂辉瑞疫苗对奥密克戎的免疫应答较弱。他们在本次研究中追踪了13个人,其中11人感染了奥密克戎毒株。他们发现,在参与者加入研究两周后,曾感染奥密克戎的人对德尔塔的抗体反应增加了四倍。同时,他们发现,奥密克戎感染对再次感染同种毒株的保护力提高了14倍。

这些发现意味着,奥密克戎可以取代德尔塔成为新冠病毒的主要毒株。由哈迪贾·可汗领导的科学家团队在研究结果中写道:“研究结果与奥密克戎将取代德尔塔变种的结论一致,因为奥密克戎变种可以引发免疫,中和德尔塔病毒,从而降低再次感染德尔塔病毒的可能性。”

科学家们指出,如果奥密克戎取代了德尔塔,且如果奥密克戎确实如早期研究结果所述不易产生重症,“新冠肺炎重症的发病率将降低,病毒感染对个体和社会的影响将变小。”尽管存在上述预测,世界卫生组织仍警告称,现在断言奥米克戎总体上是否更温和还为时过早。

俄勒冈健康与科学大学(Oregon Health & Science University)的另外一项研究发现,已接种疫苗者若出现突破性感染,可形成“超级免疫”。该研究对比了该大学52名曾接种过辉瑞疫苗但出现突破性感染的员工的血液样本,这些员工感染的毒株包括阿尔法、贝塔、伽马和德尔塔。

研究发现,突破性感染出现后产生的抗体,比接种完辉瑞疫苗第二针两周后产生的抗体更多、更有效。“没有比这更好的免疫应答了,”报告作者、俄勒冈健康与科学大学医学院助理教授菲卡杜·塔费瑟说。

“我们没有专门研究奥密克戎毒株的情况,”塔费瑟补充说,“但根据研究结果,我们预计,奥密克戎毒株产生的突破性感染将在已接种疫苗的人群中产生同样强烈的免疫反应。”

鉴于这波疫情中感染新冠肺炎病毒的人数众多,如感染者的免疫力提高,或许意味着疫情可能很快会缓解。“急速上升的感染人数正在逐步建立起群体免疫力。这将对抑制未来的疫情扩散至关重要,”凯撒家庭基金会(Kaiser Family Foundation)全球卫生政策副主任约书亚·米肖向Vox表示。

然而,奥密克戎已被证明能够很好地避开以前不同变种的感染。来自南非的预印本研究论文发现,南非第四波疫情期间,再次感染奥密克戎的风险远远高于该国第二波和第三波疫情期间再次感染的风险,上两波疫情分别以贝塔和德尔塔为主。伦敦帝国理工学院的另一项研究发现,再次感染奥密克戎变种的风险是德尔塔变种的5.4倍。(财富中文网)

译者:Agatha

If you recently tested positive and have since recovered from COVID-19, do you now have free rein to do whatever you want? According to recent studies, prior infection vastly reduces your odds of reinfection.

While some early research has led to promising findings about post-Omicron immunity, it's important to remember that most people can't be sure which strain of SARS-CoV-2 infected them. In the United States, the Omicron variant now represents 59% of COVID-19 cases, and the Delta variant accounts for the remaining 41%, according to CDC estimates. At this juncture, there is little data on the reinfection rates of each strain. One preprint study in South Africa, however, has found that an Omicron infection may increase immunity to the Delta variant.

The study, conducted by the Africa Health Research Institute—the same researchers who first found that two doses of the Pfizer vaccine elicited a weaker immune response against Omicron—followed 13 people, 11 of whom had been infected with the Omicron variant. They found that the antibody response in people previously infected with Omicron increased protection against Delta fourfold two weeks after participants joined the study. Meanwhile, they found prior Omicron infection increased protection against Omicron reinfection 14-fold.

These findings imply Omicron could displace Delta as the dominant strain of the virus. “These results are consistent with Omicron displacing the Delta variant, since it can elicit immunity which neutralizes Delta making re-infection with Delta less likely,” the team of scientists, led by Khadija Khan, wrote in their findings.

The scientists note that if Omicron displaces Delta, and if Omicron indeed causes less severe symptoms as early findings have indicated, “the incidence of COVID-19 severe disease would be reduced and the infection may shift to become less disruptive to individuals and society.” Despite these forecasts, the World Health Organization has warned that it is too soon to assert whether Omicron is milder overall.

Another study, conducted by Oregon Health & Science University, found that a breakthrough infection in a vaccinated person leads to “super immunity." The study compared blood samples from 52 Pfizer-vaccinated employees of the university infected with different strains of the virus—Alpha, Beta, Gamma, and Delta.

The study found that antibodies measured after breakthrough cases were more abundant and more effective than antibodies generated two weeks after a second dose of the Pfizer vaccine. “You can’t get a better immune response than this,” said Fikadu Tafesse, the author of the report and an assistant professor at the OHSU School of Medicine.

“We have not examined the Omicron variant specifically," Tafesse added, "but based on the results of this study we would anticipate that breakthrough infections from the Omicron variant will generate a similarly strong immune response among vaccinated people."

Greater immunity, given the vast number of people contracting COVID-19 during the current surge, may mean the pandemic may soon ease up. “The incredible number of infections is building up population-level immunity. That’ll be crucial in terms of muting future waves,” Joshua Michaud, associate director for global health policy at the Kaiser Family Foundation, told Vox.

That being said, the Omicron variant is proving adept at evading prior infections from different variants. Preprint studies from South Africa found the risk of reinfection with Omicron during South Africa’s fourth wave was substantially higher than the risk seen during the country’s second and third waves, which were dominated by Beta and Delta, respectively. Another study from the Imperial College of London found risk of reinfection with the Omicron variant was 5.4 times greater than that of the Delta variant.

财富中文网所刊载内容之知识产权为财富媒体知识产权有限公司及/或相关权利人专属所有或持有。未经许可,禁止进行转载、摘编、复制及建立镜像等任何使用。
0条Plus
精彩评论
评论

撰写或查看更多评论

请打开财富Plus APP

前往打开